These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 14658947

  • 1. Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs.
    Phelan KM, Mosholder AD, Lu S.
    J Clin Psychiatry; 2003 Nov; 64(11):1328-34. PubMed ID: 14658947
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs.
    Quiralte J, Delgado J, Sáenz de San Pedro B, López-Pascual E, Nieto MA, Ortega N, Florido JF, Conde J.
    Ann Allergy Asthma Immunol; 2004 Oct; 93(4):360-4. PubMed ID: 15521372
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
    Harley C, Wagner S.
    Clin Ther; 2003 Jan; 25(1):139-49. PubMed ID: 12637116
    [Abstract] [Full Text] [Related]

  • 10. [First spontaneous reports of adverse reactions to the new selective COX-2 non-steroidal anti-inflammatory drugs].
    Pedrós C, Cereza G, Laporte JR.
    Med Clin (Barc); 2002 Mar 30; 118(11):415-7. PubMed ID: 11943104
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 30; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [Abstract] [Full Text] [Related]

  • 17. Are rofecoxib and celecoxib safer NSAIDS?
    Drug Ther Bull; 2000 Nov 30; 38(11):81-6. PubMed ID: 11138599
    [Abstract] [Full Text] [Related]

  • 18. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
    Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, Austin PC, Laupacis A, Stukel TA.
    Lancet; 2004 May 29; 363(9423):1751-6. PubMed ID: 15172772
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.